<DOC>
	<DOCNO>NCT00005882</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use eflornithine sulindac may effective way prevent development colorectal cancer patient surgery remove benign colorectal polyp . PURPOSE : Randomized , double-blinded , phase II trial determine effectiveness eflornithine plus sulindac compare placebo prevent colorectal cancer patient surgery remove benign colorectal polyp .</brief_summary>
	<brief_title>Eflornithine Plus Sulindac Preventing Colorectal Cancer Patients With Benign Colorectal Polyps</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy eflornithine ( DFMO ) sulindac vs placebo modulate panel surrogate endpoint biomarkers ( SEB ) particular relevance colorectal neoplasia , include quantitative histopathology , uninduced apoptosis , proliferative ( Ki67 ) preneoplastic ( CEA , sialyl-TN , p53 , bcl-2 ) feature , polyamine PGE2 level patient least one previously resect colorectal adenoma . - Determine relationship modulation SEB flat mucosa development interval incident colorectal adenoma patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord aspirin use ( yes v ) participate center . Patients receive oral placebo daily first 4 week . Patients compliant take placebo 5 7 day week randomize one two treatment arm . - Arm I : Patients receive oral sulindac oral eflornithine ( DFMO ) daily . - Arm II : Patients receive oral placebo daily . Treatment continue 3 year absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : Approximately 240 patient ( 120 per treatment arm ) accrue study within 18 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At least 1 prior resect colorectal adenoma within past 5 year At least 3 mm size No personal family history familial adenomatous polyposis PATIENT CHARACTERISTICS : Age : 40 80 Performance status : SWOG 01 Life expectancy : Not specify Hematopoietic : Hematocrit least 35 % WBC least 4,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2.0 mg/dL AST ALT great 2 time normal Renal : Creatinine great 1.5 mg/dL No great 1+ protein , 03 cast , 05 WBCs RBCs urine Gastrointestinal : No requirement special diet additives No diet would preclude take study medication No gastric duodenal ulcer within past year No inflammatory bowel disease Other : No 20 dB hear loss age frequency No prior concurrent invasive cancer within past 5 year except nonmelanomatous skin cancer , melanoma situ , stage I cervical cancer , stage I colon cancer , stage 0 chronic lymphocytic leukemia No severe metabolic disorder acute chronic diseases No history predisposition abnormal wound heal repair No allergy nonsteroidal antiinflammatories eflornithine Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroid Radiotherapy : No concurrent radiotherapy Surgery : See Disease Characteristics Other : No concurrent nonsteroidal antiinflammatories anticoagulant administer regular predictable intermittent basis No concurrent aspirin great 81 mg per day 325 mg twice week cardiovascular disease prophylaxis No concurrent calcium supplement great 500 mg/day</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
</DOC>